Skip to main content
Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study

Fig. 2

Change from baseline in WOMAC Subscale Scores over time (Full Analysis Set). CI, confidence interval (calculated using Dunnett-corrected t-value); JTA-200/2, group of patients receiving an injection of JTA-004 with 200 μg clonidine and 20 mg hyaluronic acid; reference, group of patients receiving an injection of the reference treatment (hylan G-F 20); WOMAC, Western Ontario McMaster Universities. Panel a: Change from baseline in WOMAC Pain Subscale Score. Panel b: Change from baseline in WOMAC Physical Function Subscale Score. Changes from baseline in WOMAC Subscale Scores over time were evaluated using a Mixed-effect Model for Repeated Measurements with absolute change from baseline to the visit in WOMAC Subscale Score as response variable, treatment group and visit as factors, baseline WOMAC Subscale Score as covariate and treatment group-visit interaction

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us